drugset / Trial / NCT02318303

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303

Phase 2 Completed 1111 enrolled Glenmark Pharmaceuticals Ltd. India
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.

Timeline

Start
2014-12
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mometasone Other / unclassified 25 ug Intranasal
Comparator Mometasone Other / unclassified 50 ug Intranasal
Comparator Olopatadine Other / unclassified 665 ug Intranasal